These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 33811778)

  • 21. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk SNP-mediated LINC01614 upregulation drives head and neck squamous cell carcinoma progression via PI3K/AKT signaling pathway.
    Hou Y; Zhou M; Li Y; Tian T; Sun X; Chen M; Xu W; Lu M
    Mol Carcinog; 2022 Aug; 61(8):797-811. PubMed ID: 35687049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
    Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
    Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing novel long non-coding RNA FKBP9P1 represses malignant progression and inhibits PI3K/AKT signaling of head and neck squamous cell carcinoma in vitro.
    Yang YF; Feng L; Shi Q; Ma HZ; He SZ; Hou LZ; Wang R; Fang JG
    Chin Med J (Engl); 2020 Sep; 133(17):2037-2043. PubMed ID: 32769488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
    Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway.
    Koenigsberg C; Ondrey FG
    Anticancer Res; 2020 Oct; 40(10):5417-5421. PubMed ID: 32988862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway.
    Yang J; Zhu XJ; Jin MZ; Cao ZW; Ren YY; Gu ZW
    Chem Biol Interact; 2020 Jan; 316():108934. PubMed ID: 31870840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway.
    Hu J; Li G; Liu Z; Ma H; Yuan W; Lu Z; Zhang D; Ling H; Zhang F; Liu Y; Liu C; Qiu Y
    Mol Carcinog; 2023 May; 62(5):628-640. PubMed ID: 36727616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UBE2C promotes the progression of head and neck squamous cell carcinoma.
    Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
    Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LASP1 promotes proliferation, metastasis, invasion in head and neck squamous cell carcinoma and through direct interaction with HSPA1A.
    Chen Q; Wu K; Qin X; Yu Y; Wang X; Wei K
    J Cell Mol Med; 2020 Jan; 24(2):1626-1639. PubMed ID: 31793711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma.
    Shah PA; Sambandam V; Fernandez AM; Zhao H; Mazumdar T; Shen L; Wang Q; Ahmed KM; Ghosh S; Frederick MJ; Wang J; Johnson FM
    Cancer Res; 2022 Dec; 82(23):4444-4456. PubMed ID: 36169922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SFRP1 mediates cancer-associated fibroblasts to suppress cancer cell proliferation and migration in head and neck squamous cell carcinoma.
    Dong L; Li Y; Song X; Sun C; Song X
    BMC Cancer; 2024 Sep; 24(1):1165. PubMed ID: 39300373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Context-Dependent Regulation of Peripheral Nerve Abundance by the PI3K Pathway in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma.
    Khorani K; Burkart S; Weusthof C; Han R; Liang S; Stögbauer F; Hess J
    Cells; 2024 Jun; 13(12):. PubMed ID: 38920662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
    Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
    Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lactate dehydrogenase B as a metabolism-related marker for immunotherapy in head and neck squamous cell carcinoma.
    Xu X; Pan X; Fan Z; Xia J; Ren X
    Cell Signal; 2024 Aug; 120():111200. PubMed ID: 38719019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
    Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
    Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
    Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
    Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma.
    Georgy SR; Cangkrama M; Srivastava S; Partridge D; Auden A; Dworkin S; McLean CA; Jane SM; Darido C
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26063791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.